11,201 Shares in IQVIA Holdings Inc. (NYSE:IQV) Purchased by Graham Capital Management L.P.

Graham Capital Management L.P. acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 11,201 shares of the medical research company’s stock, valued at approximately $2,201,000.

Several other large investors have also made changes to their positions in the business. Smith Group Asset Management LLC acquired a new stake in shares of IQVIA during the 4th quarter valued at about $1,616,000. Hickory Asset Management Inc. acquired a new stake in shares of IQVIA during the 4th quarter valued at about $941,000. Fifth Third Bancorp grew its stake in shares of IQVIA by 13.0% in the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock valued at $2,590,000 after purchasing an additional 1,521 shares during the period. Graphene Investments SAS grew its stake in shares of IQVIA by 22.0% in the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company’s stock valued at $2,948,000 after purchasing an additional 2,700 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in shares of IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after purchasing an additional 583,396 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Down 2.9%

Shares of IQV opened at $148.90 on Monday. IQVIA Holdings Inc. has a 52 week low of $135.97 and a 52 week high of $252.88. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The firm has a market capitalization of $25.76 billion, a price-to-earnings ratio of 19.85, a PEG ratio of 1.99 and a beta of 1.34. The business’s fifty day moving average price is $163.91 and its two-hundred day moving average price is $188.09.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.07. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The business had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. During the same period last year, the company earned $2.54 EPS. The firm’s revenue was up 2.5% on a year-over-year basis. On average, analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

IQV has been the topic of several analyst reports. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. Robert W. Baird lowered their price objective on IQVIA from $195.00 to $161.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 7th. Mizuho lowered their price objective on IQVIA from $242.00 to $210.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 9th. Barclays decreased their price target on IQVIA from $170.00 to $165.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 7th. Finally, Hsbc Global Res lowered IQVIA from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 25th. Eight analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $231.71.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.